Медицинский совет (Apr 2018)
The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease
Abstract
The flexible dosage form combined with the increased maintenance of a therapeutic dextensoprazole concentration in plasma with a modified release and prolonged inhibition of acid secretion after administration of the drug suggests that dexlansoprozole has several advantages for patients with acid-dependent diseases. The pharmacokinetic profile of dexlansoprazole is characterized by two Tmax peaks in 1–2 and 4–5 hours after administrating the drug and ensures a stable concentration of it in the blood. The efficacy of dexlansoprozole in the treatment of various forms of gastroesophageal reflux disease has been confirmed by several randomized controlled clinical trials.
Keywords